Genotypic characterization of gentamicin and cephalosporin resistant

Øyvind Andreas Fladberg, Silje Bakken Jørgensen, Hege Vangstein Aamot

Open access · goldAbstract read

In one paragraph

Article in Antimicrobial resistance and infection control, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 56% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

Expansion of a Subset Within the C2 Subclade ofOpen forum infectious diseases · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Øyvind Andreas FladbergDepartment of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway.

Silje Bakken JørgensenDepartment of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway.

Hege Vangstein AamotDepartment of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0002-3176-8560

Akershus University Hospital · NOUniversity of Oslo · NOUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cephalosporin resistance in clinical Methods: In Norway, recommended empirical treatment of sepsis consists of gentamicin and penicillin combined, or a broad-spectrum cephalosporin. To investigate if increased gentamicin and cephalosporins resistance rates in our hospital could be caused by specific clones, we conducted a retrospective study on Results: A total of 158 cephalosporin and/or gentamicin resistant and 97 control isolates were differentiated into 126 unique MLVA types. Of these, 31% of the isolates belonged to a major MLVA cluster consisting of 41% of the gentamicin resistant and 35% of the cephalosporin resistant isolates. The majority (65/80 isolates) of this MLVA cluster contained MLVA types associated with the Conclusion: No local

Indexed as

BacteremiaCross InfectionDrug Resistance, BacterialGenotypeBacterial Proteinsbeta-LactamasesCephalosporinsCross-Sectional StudiesEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsGentamicinsHumansMinisatellite RepeatsMultilocus Sequence TypingNorwayAmpC beta-lactamasesBacterial Proteinsbeta-lactamase CTX-M, E colibeta-LactamasesCephalosporinsEscherichia coli ProteinsGentamicinsAmpCAntibiotic resistanceBacteraemiaCTX-ME. coliESBLGenotypingMLVASurveillance

Identifiers

PMID29214016

DOI10.1186/s13756-017-0280-2

PMCPMC5707821

OpenAlexW2769377470

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.